- Effective June 30, 2025, Ainos (AIMD, Financial) will execute a 1-for-5 reverse stock split.
- The consolidation aims to attract institutional investors and ensure compliance with Nasdaq listing requirements.
- Ainos's strategic focus in 2H 2025 includes the AI Nose platform and VELDONA® clinical developments.
Ainos, Inc. (NASDAQ:AIMD) has announced a reverse stock split in which every five existing shares of common stock will be consolidated into one new share, effective on June 30, 2025. This restructuring strategy seeks to elevate the stock price and ensure compliance with the Nasdaq's minimum bid price requirement, while also making the stock more attractive to institutional investors. Fractional shares resulting from the split will be paid out in cash to shareholders.
Ahead of its commercial execution phase in the second half of 2025, Ainos is actively focusing on two core verticals. The first is the AI Nose platform, an AI-powered scent digitization technology that will undergo scaled field testing across various industries such as senior care, robotics, and semiconductor manufacturing. The second is the VELDONA® product line, a low-dose oral interferon currently in clinical development targeting human conditions like Sjögren's syndrome and HIV-related oral warts, along with veterinary applications such as feline chronic gingivostomatitis.
Post-consolidation, the number of Ainos shares will decrease, but the stock price is expected to adjust accordingly, multiplying approximately by five times its pre-consolidation price. The stock will continue to trade under the Nasdaq ticker symbol AIMD, with a new CUSIP number, 00902F402, for tracking.
